{"ticker": {"uuid": "53119caa-df1b-4071-8f1a-414ee9e122a0", "symbol": "GYRE", "name": "Gyre Therapeutics Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Gyre Therapeutics Appoints Three New Members to its Board of Directors", "summary": "Gyre Therapeutics has appointed Yue Xiong, Ph.D., Maxwell Kirkby, and Claire Weston, Ph.D., to its Board of Directors, effective August 1, 2026. These appointments aim to enhance the company's expertise in scientific, clinical development, and cross-border biopharmaceutical opera", "url": "https://www.manilatimes.net/2026/07/17/tmt-newswire/globenewswire/gyre-therapeutics-appoints-three-new-members-to-its-board-of-directors/2386245/amp", "source_name": "The Manila Times", "published_at": "2026-07-17T06:39:48", "published_display": "17 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics appoints three directors to board By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQZ1lCZGN6Y28yZERzN05EZWo4aHN1WGdSYWZmWFZqLVdXSlhlWS1OTmUtb0w1NUEtcUM0WHlmNGZMT3pOcUNxQ2RZN0RGczdqcjctQTdiZ1c3VlBOd25GczVEd3BrU0VIZkR5S01DelZEVDRucGhZa2pYRUZRVVlJaUdvd2Uxc3RPeWI4UDhpeDJocGpLVnVuS0dPVHhiOVRkbEY0QVBZS1lnS2d5eTA3M3p3?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T21:13:53+00:00", "published_display": "16 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gyre Therapeutics appoints three directors to board", "summary": "Gyre Therapeutics announced the appointment of three new directors to its Board, effective August 1, 2026: Dr. Yue Xiong as Chief Scientific Officer, Maxwell Kirkby, and Dr. Claire Weston. This follows recent significant activities for the company, including the acquisition of Cu", "url": "https://www.investing.com/news/company-news/gyre-therapeutics-appoints-three-directors-to-board-93CH-4796727", "source_name": "Investing.com", "published_at": "2026-07-16T19:10:45", "published_display": "16 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (Nasdaq: GYRE) adds three directors, expanding expertise", "summary": "Gyre Therapeutics announced the appointment of three new directors to its board, effective August 1, 2026: Dr. Yue Xiong, Maxwell Kirkby, and Dr. Claire Weston. These additions aim to expand the company's expertise in scientific, clinical development, and cross-border biopharmace", "url": "https://www.stocktitan.net/sec-filings/GYRE/8-k-gyre-therapeutics-inc-reports-material-event-5b8fb130d7ae.html", "source_name": "Stock Titan", "published_at": "2026-07-16T18:10:46", "published_display": "16 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Adds Director With Drug Development Experience Across China, Japan", "summary": "Gyre Therapeutics has appointed three new directors to its Board, effective August 1, 2026: Yue Xiong, Maxwell Kirkby, and Claire Weston. These appointments aim to bolster the company's scientific, clinical development, governance, and cross-border biopharmaceutical expertise as ", "url": "https://www.stocktitan.net/news/GYRE/gyre-therapeutics-appoints-three-new-members-to-its-board-of-m12va3e0ik7o.html", "source_name": "Stock Titan", "published_at": "2026-07-16T18:10:45", "published_display": "16 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) Registration filing Summary", "summary": "Gyre Therapeutics (GYRE) has filed a registration summary, detailing its focus as a commercial-stage biopharmaceutical company specializing in small-molecule therapies for organ fibrosis and inflammatory diseases. The company recently merged with Cullgen, expanding its therapeuti", "url": "https://quartr.com/events/gyre-therapeutics-inc-gyre-registration-filing_F3sNNn6y", "source_name": "Quartr", "published_at": "2026-07-16T02:43:13", "published_display": "16 Jul 2026 02:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullgen $300M all-stock deal expands Gyre Therapeutics (Nasdaq: GYRE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQU25fUkxiclVBZ3V1VllYcWp0cmc4QVA1S1NwQXFWUGtjYW5MNFd2UmVITGxzelJNcElqLVJhSGlCa3pOX1d5YXJxWlpBazJiR0lUS2pXVGhveHFhaVdYQ0NFUUZHSi1xS25pdjlEcUxubWEwQWh3ZjIwcUFiakJBU1RUMU8zeHdwQ2ZNT0t4Q3JRUmNVWnFRUEtXTE4tVXhiNTRZZl9OTWVaUi1Qa200UklHazZ2UDhXUkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T21:09:36+00:00", "published_display": "15 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3/A Gyre Therapeutics Inc For: 13 July By Investing.com", "summary": "This article announces the filing of Form S-3/A by Gyre Therapeutics Inc for July 13. It is a brief report from Investing.com, providing financial news regarding the company. The article also lists various market data and other news headlines.", "url": "https://au.investing.com/news/stock-market-news/form-s3a-gyre-therapeutics-inc-for-13-july-93CH-4530822", "source_name": "Investing.com Australia", "published_at": "2026-07-14T17:43:13", "published_display": "14 Jul 2026 17:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (Nasdaq: GYRE) details 31.3M-share resale and China risks", "summary": "Gyre Therapeutics has filed an amended S-3 registration statement to allow for the resale of up to 31.3 million shares by existing stockholders, an increase from its original registration. The company highlighted significant legal and regulatory risks associated with its operatio", "url": "https://www.stocktitan.net/sec-filings/GYRE/s-3-a-gyre-therapeutics-inc-amended-shelf-registration-statement-223bfc8b75a6.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:11:50", "published_display": "13 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gyre Therapeutics highlights pipeline progress as investors watch fibrosis focus", "summary": "Gyre Therapeutics is gaining investor attention due to its specialization in therapies for fibrotic and inflammatory diseases, which address significant unmet medical needs. The company's core strategy is to develop drug candidates targeting key pathways in fibrosis, aiming to sl", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/gyre-therapeutics-highlights-pipeline-progress-as-investors-watch-fibrosis/69716465", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:48:00", "published_display": "07 Jul 2026 19:48", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Gyre Therapeutics Inc (GYRE)", "summary": "This article analyzes the historical performance of a $1,000 investment in Gyre Therapeutics Inc (GYRE) over various periods, showing significant negative returns. It also provides an overview of Gyre Therapeutics, a biopharmaceutical company focused on fibrosis-first therapies, ", "url": "https://www.stocktitan.net/tools/stock-return-calculator/GYRE", "source_name": "Stock Titan", "published_at": "2026-07-04T06:09:25", "published_display": "04 Jul 2026 06:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GYRE - Gyre Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Gyre Therapeutics Inc (GYRE), including its last closing price, dollar and percentage change, and various financial metrics such as market cap, income, sales, and employee count. It also lists key financial ratios like P/E, P", "url": "https://finviz.com/quote?t=GYRE&ty=oc&p=d&b=1&ov=chain_strike&s=10", "source_name": "Finviz", "published_at": "2026-07-03T07:40:48", "published_display": "03 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GYRE SEC Filings - Gyre Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Gyre Therapeutics (GYRE) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It details recent insider stock option grants to multiple directors and a COO's share transactions, alon", "url": "https://www.stocktitan.net/sec-filings/GYRE/", "source_name": "Stock Titan", "published_at": "2026-07-01T13:13:27", "published_display": "01 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Gyre Therapeutics Inc For: 30 June By Investing.com", "summary": "This article from Investing.com announces the Form 4 filing for Gyre Therapeutics Inc., reflecting transactions made through June 30. The content primarily consists of market data, including indices, commodities, bonds, and shares, along with trending stocks and a series of other", "url": "https://ng.investing.com/news/stock-market-news/form-4-gyre-therapeutics-inc-for-30-june-93CH-2581229", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T13:13:27", "published_display": "01 Jul 2026 13:13", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (NASDAQ: GYRE) director awarded 40,000 stock options at $5.95", "summary": "Gyre Therapeutics director Renate Parry was granted 40,000 stock options with an exercise price of $5.95 per share, expiring on June 10, 2036. The options will vest in 12 equal monthly installments through June 10, 2027, contingent on her continued service. This award is compensa", "url": "https://www.stocktitan.net/sec-filings/GYRE/form-4-gyre-therapeutics-inc-insider-trading-activity-3434d7ea286f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T22:39:24", "published_display": "30 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95", "summary": "Gyre Therapeutics (GYRE) director Zhang Ping was granted 40,000 stock options with an exercise price of $5.95 per share. These options are set to expire on June 10, 2036, and will vest in 12 equal monthly installments through June 10, 2027, provided service continues. This transa", "url": "https://www.stocktitan.net/sec-filings/GYRE/form-4-gyre-therapeutics-inc-insider-trading-activity-3604dcfecbfa.html", "source_name": "Stock Titan", "published_at": "2026-06-30T22:39:24", "published_display": "30 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Rodney Nussbaum awarded 40,000 Gyre Therapeutics (GYRE) stock options", "summary": "Gyre Therapeutics director Rodney L. Nussbaum was granted 40,000 stock options with an exercise price of $5.95 per share, expiring on June 10, 2036. This compensation-related award will vest in 12 equal monthly installments through June 10, 2027, provided his continued service to", "url": "https://www.stocktitan.net/sec-filings/GYRE/form-4-gyre-therapeutics-inc-insider-trading-activity-2e503c3854ea.html", "source_name": "Stock Titan", "published_at": "2026-06-30T22:39:23", "published_display": "30 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US High Growth Tech Stocks to Watch", "summary": "This article highlights top-performing high-growth tech stocks in the U.S., emphasizing strong innovation and adaptability. It reviews companies like Gyre Therapeutics, Neurocrine Biosciences, and Procore Technologies, detailing their recent developments, revenue growth, and mark", "url": "https://simplywall.st/stocks/us/software/nyse-pcor/procore-technologies/news/us-high-growth-tech-stocks-to-watch-15/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-30T17:39:23", "published_display": "30 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM:GYRE) added to Russell Small Cap Comp Value Benchmark", "summary": "Gyre Therapeutics, Inc. (NasdaqCM:GYRE) has been added to the Russell Small Cap Comp Value Benchmark. This inclusion follows several recent additions to various Russell indices, including the Russell 2000 Value, Russell 2000 Value-Defensive, Russell 2000 Growth-Defensive, Russell", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfd080f025", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:40:29", "published_display": "29 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value Benchmark", "summary": "Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 2000 Value Benchmark, according to a report published on June 29, 2026, by S&P Capital IQ. The biopharmaceutical company is focused on developing and commercializing therapies for liver fibrosis and other cond", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-2000-value-benchmark-ce7f5fdfd880f624", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:00:00", "published_display": "29 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm", "summary": "Kaskela Law LLC has initiated a shareholder investigation into Gyre Therapeutics, Inc. (NASDAQ: GYRE) to determine if the company's officers and directors violated securities laws or breached fiduciary duties. The firm encourages long-term Gyre shareholders to contact them to lea", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/gyre-therapeutics-gyre-kaskela-law-llc-announces-shareholder-inv-1183583", "source_name": "ACCESS Newswire", "published_at": "2026-06-29T06:00:00", "published_display": "29 Jun 2026 06:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Growth-Defensive Index", "summary": "Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 2000 Growth-Defensive Index. This inclusion comes alongside news of the company's F351 (hydronidone) drug for liver fibrosis advancing through regulatory processes in China, with an NMPA acceptance for a new d", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-2000-growth-defensive-index-ce7f5fdedb8af423", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T02:41:59", "published_display": "29 Jun 2026 02:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value-Defensive Index", "summary": "Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 2000 Value-Defensive Index. The biopharmaceutical company is focused on developing and commercializing F351 for MASH-associated fibrosis and expanding its pipeline in the PRC through Gyre Pharmaceuticals. Rece", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-2000-value-defensive-index-ce7f5fdedb8cff24", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T02:41:58", "published_display": "29 Jun 2026 02:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 3000E Value Benchmark", "summary": "Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 3000E Value Benchmark. This inclusion follows several other recent additions to various Russell indices, including the Russell 2000 Value Benchmark, Russell 2000 Value-Defensive Index, and Russell 3000 Value B", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-3000e-value-benchmark-ce7f5fddd98bf422", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T01:08:55", "published_display": "29 Jun 2026 01:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Gyre Therapeutics, Inc. \u2013 NASDAQ:GYRE", "summary": "This page provides financial information for Gyre Therapeutics, Inc. (NASDAQ: GYRE), specifically its price to earnings forward. It is part of TradingView's market data offerings and includes various disclaimers regarding data sources.", "url": "https://www.tradingview.com/symbols/NASDAQ-GYRE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:45", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Gyre Therapeutics Inc \u2013 LS:A3EE5F", "summary": "This article provides financial data for Gyre Therapeutics Inc (LS:A3EE5F), specifically its forward price-to-earnings ratio. It is presented in a data-centric format from TradingView, offering an overview of the company's financial metrics. The content highlights the period, val", "url": "https://www.tradingview.com/symbols/LS-A3EE5F/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:38:51", "published_display": "26 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Gyre Therapeutics, Inc. \u2013 NASDAQ:GYRE", "summary": "This article focuses on the enterprise value to revenue forward metric for Gyre Therapeutics, Inc. (NASDAQ: GYRE). It indicates that the company's financial data is available for analysis on TradingView, which provides market, financial, and other relevant information for the pha", "url": "https://www.tradingview.com/symbols/NASDAQ-GYRE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:42", "published_display": "26 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Inc Actuals & Estimates (NASDAQ:GYRE)", "summary": "This article provides an overview of Gyre Therapeutics, Inc. (NASDAQ:GYRE) stock, including its current price, performance, analyst forecasts, and financial data. It covers historical price movements, volatility, market capitalization, and upcoming earnings reports, offering a co", "url": "https://www.tradingview.com/symbols/NASDAQ-GYRE/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T01:10:42", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) COO trades 11,000 shares, retains 700,000", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbzRmOWJZNGNvUDAxUUR6ZE5wNXQ1TVA3RVFybUx1TVc4Q0NFX3Fua3Jacy1YQXVYdm9ldUlHcUVLMmN5M182NXZCUU1MaDNoNElVZktpRFA3SW9tbllDNEhyS0Q3VXNWbm1SVXZyT281ZjYzZEF6WlZZMWUzby15NXkwdU9WN0dQeG00RVA4alNrcUhXekVELVdHS1BqNUtmUWJTQVAtQzhIWjdLVzgwNU1MNzAzZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Shareholders Approve Directors and Governance Measures", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQeTl1VVNZWUR0dEVObk1ieWJaZnY5cXFOektDb29ITVdsaWI5MFVjN2hUUUgwU0x4eXVPcjRkOVp1M3NqQlI4anRxeHhkajhlR1VXeDJyU2dSNXlZY0NaRVdKcjBHTWI3YWNnY3dRdWhsSklaREQwWHVmaGtkeFF0czFWcDdsTlI4X29KM3hReXEtUEhRUGpLcjR5a2JxSC0yUlhnQndYSV8xZEtWbFRua0V0UTJrbm92R1NpVHZhbnNpVm9oZVJKYkNlSEFSeDNqNGR1bEd2bnA3MThiX25XRks5YWR3c0QzTzROdnB3?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (NASDAQ: GYRE) investors back directors, pay and Series B conversion", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOdTJxeVNxN2kxUjNocGFWaVNRUXNLMzBFT2loeWxCYUJ0elhSQTRIbTViZExaQ2hSbm1xYmFxUUhJNTJGWExfTTZxQWJ0OFFmRXMzUmMzTTBpZm9zcHZLb2QxaVE4aVpkSlVSUV80N0tzU1Z3MU1WdzZ3VFdrZmZRajNnRTg2U0tBNUFKSktlSmhmdnBIRk5RQU5vbFFUY3FEMGphQ1hvZG1TbkhJd0RZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPdkFFRzV6Qjh6LUpsb3FfWm9hMEN2V1I1V2tLUUliUURleWhiTy1Eem5Kb0g2TWY4S3dwbWR4alpEZ25GN1g5czQ3cThyNnhST0hRRlJIUk1oMlVfbGxkX05IaC1ULXRpTi1JeWZ6WFB6U3UydTZ4LVpVM2xJN0ZSZWptaUpaVDRFdmtnODc5QUhYYWVtejhMZ2FVNzUzdXJLUWVDaTNLcFlQYy1ObUgxRHlWNXF2QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO of Gyre Therapeutics (NASDAQ: GYRE) receives 120,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxObkswNUtjS1FPbHJoMWpmcDluZURoaThtdkZTZWVtN3FmZVoyeWd2aERfQWZaM25lNlJfY1ZGMGx6UVU4Tk1jVnhJdDN3ZzQtQ3doTjdXNXgtRXgtUUZCODYwTXZLc3ZrQ1I5QU9mNlBockJEZFlKVEFCRTJRX2NkUmhFYkI5Tjc1b3I0dkd1dm0xTmF5Z2FIbE1oZVZSckN6VmVEcDdUQ0lQZlBPdU1BcldpS3BDdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug", "summary": "", "url": "https://finance.yahoo.com/news/gyre-therapeutics-says-china-regulator-215329042.html", "source_name": "MT Newswires", "published_at": "2026-05-12T21:53:29+00:00", "published_display": "12 May 2026 21:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment", "summary": "", "url": "https://finance.yahoo.com/news/gyre-therapeutics-announces-nmpa-acceptance-200500748.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gyre-therapeutics-reports-first-quarter-100000405.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T10:00:00+00:00", "published_display": "07 May 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOM2hGYk1kM3F2S0ZHMW01cGlyUDhlazZwZ2h6TlY2WHl4VmY5cTdaYzkzZW1WVEtVWFdYU0kwQnFpWHdLYUJyc2FuRm12WWtnRW40MWpRMHQ4aldpNzZ4QS0wTEJoSFpMMC0xVjJSTC14UHhXa0s2SVRQRFNxUkplYks2LXF3cEozNWZYZ3FJMlJPLWt1TGJtY0ltU0FUTjlOUkRHUVh3?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Completes $300 Million All-Stock Acquisition of Cullgen", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gyre-therapeutics-completes-300-million-144344832.html", "source_name": "MT Newswires", "published_at": "2026-05-04T14:43:44+00:00", "published_display": "04 May 2026 14:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gyre-therapeutics-completes-acquisition-cullgen-124700768.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T12:47:00+00:00", "published_display": "04 May 2026 12:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNdjVrMGMzeDhBckJDdkdXUm1RbVIxUDgtOGJPcUFGNkVEanFLNFdEeUw2aE9WM3YwTDBucWhPRldENTQ5Z2x3eXd3S3J1aVNxb3JYWkpVdWNKMmdNd0ZlSElONTZjYmd5ZjN6dEFLanM3Uk1uaFJBd3M4VHpKanVNU21JOEVVOU9xbEUxTA?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Enters into Agreement to Acquire Cullgen", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxNWGxnNk9YdFZ1NU5MQTlBS1dGMW5fR0VWQW1vR3N2Y0pHajJWNkdCdHBIby1WVE5RSWdnRlFoTHlvbzFzVjZER1U2dEN5b0JOaUdjRk53bzRrX1I5QjZCSllhd0dCTmZEZVBZUmM2RE4yb2NFODlJbUdYNUl3dW5vSVpGNWwwSlpuMW5pZFp3Ty14TG5XTjBsN0trdFNKYkgzSjhXNTBKSG9vZUZUaVZmX2NjbUE5RmF4d1FETG55eHlTQzcxTEczbHFHNXl3ZEN0V2JkWlQwOFE2UlNZRl9uc0pNREU2LVgzY083cC1ZSmFuaFB3UzJMVXVZdjF0U0tnWVE2dlpQMHVzdGpVUXlPUHNsalduYVk3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNODNCTkJBNVEtWi1mQlN5ZmZFdHNmQVNBZ0VoNU0tY3dBQmtlNlFoOEFmR0J5b3ktb1pMdl80VEIwSlR6bVJETEpLQXV4UHJGM1ZuSG5yc2Jqcno1MUdPenBXa2dNdlJHZ0MxTTB6UnNlbkxidFNFbFA2cFVYYVA2R2lPRTJPUkNCMXFfRVVGb2JveTY0dmF0VDFURVA3S2RMNU41R2JzSUFtVUtDOU0xdWNHOUpOWFBPUmxaNU41cmlvUmp2OVVjUnhJcWFicGJqVEIzUDJ5d3dsWVZjRkoyUHoxckFTcmJyak1VcXctSEJFRU5ZcktzYlJR?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Gyre Therapeutics Stock Recover If Markets Fall?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQeHVfT3FPRzVLbm9rWktSSmJnaXJRdTdTX001bXdhWHhjbVlTenotRGtpQVh5NHZrS3lySUJBNkhTUmNOdXVKUkxVdU1iSVF5T2JBTHBEYU1Cd1dRdFpIT1V2TVE5akFrMVlGaDAwMkxOX0REVmVzRUVWWnNiVlJrSW9sbGgzMnJPVGpDSW9scGVUYUU4ZThaa2dvZ24tN2Q5eFVLcW1PQUlJZ2pHN1ZzWHFkOTQ3VlBOand2MEJXMA?oc=5", "source_name": "Trefis", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "272 Patients Enrolled \u2014 Gyre Therapeutics' Phase 3 Pirfenidone Trial Completes at 18 China Sites", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNakhKdmRnelI2aUZLWlhKR1Ruanp4cE1JaEJwYmtrZ1NCQ1d5VHJnS1lXbFpMVXJNZ2JUMkVGWTB2TnQ4WHhtX1pGeWdXQVFfM1I3X01MWDNSTXdyakJTQlkzaDdrRVRhOW5GRy1teXBnUWM2TDNBVDhtMm82TU9rdGNqU3hDbjNOb3JFVHdCZERwQnViQ1FlX1huVFE3ajk2UFJhVjh4MWtBTG1lSWRWOTh4aEhjUllOZXc?oc=5", "source_name": "Stock Titan", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBtQjRvcXdKQjRleWlUckk4bEYyOWVGSTgwQnk2QWtQVzFjUmZrRjBmRWpIY1ZzVnkwWC1IcW9RYzhDaVVac2FCeHk5RmpvUG5FWmlJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:53:18+00:00", "published_display": "25 Apr 2025 00:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Gyre Therapeutics Appoints Three New Members to its Board of Directors", "summary": "Gyre Therapeutics has appointed Yue Xiong, Ph.D., Maxwell Kirkby, and Claire Weston, Ph.D., to its Board of Directors, effective August 1, 2026. These appointments aim to enhance the company's expertise in scientific, clinical development, and cross-border biopharmaceutical opera", "url": "https://www.manilatimes.net/2026/07/17/tmt-newswire/globenewswire/gyre-therapeutics-appoints-three-new-members-to-its-board-of-directors/2386245/amp", "source_name": "The Manila Times", "published_at": "2026-07-17T06:39:48", "published_display": "17 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics appoints three directors to board By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQZ1lCZGN6Y28yZERzN05EZWo4aHN1WGdSYWZmWFZqLVdXSlhlWS1OTmUtb0w1NUEtcUM0WHlmNGZMT3pOcUNxQ2RZN0RGczdqcjctQTdiZ1c3VlBOd25GczVEd3BrU0VIZkR5S01DelZEVDRucGhZa2pYRUZRVVlJaUdvd2Uxc3RPeWI4UDhpeDJocGpLVnVuS0dPVHhiOVRkbEY0QVBZS1lnS2d5eTA3M3p3?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T21:13:53+00:00", "published_display": "16 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics appoints three directors to board", "summary": "Gyre Therapeutics announced the appointment of three new directors to its Board, effective August 1, 2026: Dr. Yue Xiong as Chief Scientific Officer, Maxwell Kirkby, and Dr. Claire Weston. This follows recent significant activities for the company, including the acquisition of Cu", "url": "https://www.investing.com/news/company-news/gyre-therapeutics-appoints-three-directors-to-board-93CH-4796727", "source_name": "Investing.com", "published_at": "2026-07-16T19:10:45", "published_display": "16 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (Nasdaq: GYRE) adds three directors, expanding expertise", "summary": "Gyre Therapeutics announced the appointment of three new directors to its board, effective August 1, 2026: Dr. Yue Xiong, Maxwell Kirkby, and Dr. Claire Weston. These additions aim to expand the company's expertise in scientific, clinical development, and cross-border biopharmace", "url": "https://www.stocktitan.net/sec-filings/GYRE/8-k-gyre-therapeutics-inc-reports-material-event-5b8fb130d7ae.html", "source_name": "Stock Titan", "published_at": "2026-07-16T18:10:46", "published_display": "16 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Adds Director With Drug Development Experience Across China, Japan", "summary": "Gyre Therapeutics has appointed three new directors to its Board, effective August 1, 2026: Yue Xiong, Maxwell Kirkby, and Claire Weston. These appointments aim to bolster the company's scientific, clinical development, governance, and cross-border biopharmaceutical expertise as ", "url": "https://www.stocktitan.net/news/GYRE/gyre-therapeutics-appoints-three-new-members-to-its-board-of-m12va3e0ik7o.html", "source_name": "Stock Titan", "published_at": "2026-07-16T18:10:45", "published_display": "16 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) Registration filing Summary", "summary": "Gyre Therapeutics (GYRE) has filed a registration summary, detailing its focus as a commercial-stage biopharmaceutical company specializing in small-molecule therapies for organ fibrosis and inflammatory diseases. The company recently merged with Cullgen, expanding its therapeuti", "url": "https://quartr.com/events/gyre-therapeutics-inc-gyre-registration-filing_F3sNNn6y", "source_name": "Quartr", "published_at": "2026-07-16T02:43:13", "published_display": "16 Jul 2026 02:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cullgen $300M all-stock deal expands Gyre Therapeutics (Nasdaq: GYRE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQU25fUkxiclVBZ3V1VllYcWp0cmc4QVA1S1NwQXFWUGtjYW5MNFd2UmVITGxzelJNcElqLVJhSGlCa3pOX1d5YXJxWlpBazJiR0lUS2pXVGhveHFhaVdYQ0NFUUZHSi1xS25pdjlEcUxubWEwQWh3ZjIwcUFiakJBU1RUMU8zeHdwQ2ZNT0t4Q3JRUmNVWnFRUEtXTE4tVXhiNTRZZl9OTWVaUi1Qa200UklHazZ2UDhXUkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T21:09:36+00:00", "published_display": "15 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3/A Gyre Therapeutics Inc For: 13 July By Investing.com", "summary": "This article announces the filing of Form S-3/A by Gyre Therapeutics Inc for July 13. It is a brief report from Investing.com, providing financial news regarding the company. The article also lists various market data and other news headlines.", "url": "https://au.investing.com/news/stock-market-news/form-s3a-gyre-therapeutics-inc-for-13-july-93CH-4530822", "source_name": "Investing.com Australia", "published_at": "2026-07-14T17:43:13", "published_display": "14 Jul 2026 17:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (Nasdaq: GYRE) details 31.3M-share resale and China risks", "summary": "Gyre Therapeutics has filed an amended S-3 registration statement to allow for the resale of up to 31.3 million shares by existing stockholders, an increase from its original registration. The company highlighted significant legal and regulatory risks associated with its operatio", "url": "https://www.stocktitan.net/sec-filings/GYRE/s-3-a-gyre-therapeutics-inc-amended-shelf-registration-statement-223bfc8b75a6.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:11:50", "published_display": "13 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics highlights pipeline progress as investors watch fibrosis focus", "summary": "Gyre Therapeutics is gaining investor attention due to its specialization in therapies for fibrotic and inflammatory diseases, which address significant unmet medical needs. The company's core strategy is to develop drug candidates targeting key pathways in fibrosis, aiming to sl", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/gyre-therapeutics-highlights-pipeline-progress-as-investors-watch-fibrosis/69716465", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:48:00", "published_display": "07 Jul 2026 19:48", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Gyre Therapeutics Inc (GYRE)", "summary": "This article analyzes the historical performance of a $1,000 investment in Gyre Therapeutics Inc (GYRE) over various periods, showing significant negative returns. It also provides an overview of Gyre Therapeutics, a biopharmaceutical company focused on fibrosis-first therapies, ", "url": "https://www.stocktitan.net/tools/stock-return-calculator/GYRE", "source_name": "Stock Titan", "published_at": "2026-07-04T06:09:25", "published_display": "04 Jul 2026 06:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GYRE - Gyre Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Gyre Therapeutics Inc (GYRE), including its last closing price, dollar and percentage change, and various financial metrics such as market cap, income, sales, and employee count. It also lists key financial ratios like P/E, P", "url": "https://finviz.com/quote?t=GYRE&ty=oc&p=d&b=1&ov=chain_strike&s=10", "source_name": "Finviz", "published_at": "2026-07-03T07:40:48", "published_display": "03 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GYRE SEC Filings - Gyre Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Gyre Therapeutics (GYRE) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It details recent insider stock option grants to multiple directors and a COO's share transactions, alon", "url": "https://www.stocktitan.net/sec-filings/GYRE/", "source_name": "Stock Titan", "published_at": "2026-07-01T13:13:27", "published_display": "01 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Gyre Therapeutics Inc For: 30 June By Investing.com", "summary": "This article from Investing.com announces the Form 4 filing for Gyre Therapeutics Inc., reflecting transactions made through June 30. The content primarily consists of market data, including indices, commodities, bonds, and shares, along with trending stocks and a series of other", "url": "https://ng.investing.com/news/stock-market-news/form-4-gyre-therapeutics-inc-for-30-june-93CH-2581229", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T13:13:27", "published_display": "01 Jul 2026 13:13", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (NASDAQ: GYRE) director awarded 40,000 stock options at $5.95", "summary": "Gyre Therapeutics director Renate Parry was granted 40,000 stock options with an exercise price of $5.95 per share, expiring on June 10, 2036. The options will vest in 12 equal monthly installments through June 10, 2027, contingent on her continued service. This award is compensa", "url": "https://www.stocktitan.net/sec-filings/GYRE/form-4-gyre-therapeutics-inc-insider-trading-activity-3434d7ea286f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T22:39:24", "published_display": "30 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95", "summary": "Gyre Therapeutics (GYRE) director Zhang Ping was granted 40,000 stock options with an exercise price of $5.95 per share. These options are set to expire on June 10, 2036, and will vest in 12 equal monthly installments through June 10, 2027, provided service continues. This transa", "url": "https://www.stocktitan.net/sec-filings/GYRE/form-4-gyre-therapeutics-inc-insider-trading-activity-3604dcfecbfa.html", "source_name": "Stock Titan", "published_at": "2026-06-30T22:39:24", "published_display": "30 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Rodney Nussbaum awarded 40,000 Gyre Therapeutics (GYRE) stock options", "summary": "Gyre Therapeutics director Rodney L. Nussbaum was granted 40,000 stock options with an exercise price of $5.95 per share, expiring on June 10, 2036. This compensation-related award will vest in 12 equal monthly installments through June 10, 2027, provided his continued service to", "url": "https://www.stocktitan.net/sec-filings/GYRE/form-4-gyre-therapeutics-inc-insider-trading-activity-2e503c3854ea.html", "source_name": "Stock Titan", "published_at": "2026-06-30T22:39:23", "published_display": "30 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US High Growth Tech Stocks to Watch", "summary": "This article highlights top-performing high-growth tech stocks in the U.S., emphasizing strong innovation and adaptability. It reviews companies like Gyre Therapeutics, Neurocrine Biosciences, and Procore Technologies, detailing their recent developments, revenue growth, and mark", "url": "https://simplywall.st/stocks/us/software/nyse-pcor/procore-technologies/news/us-high-growth-tech-stocks-to-watch-15/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-30T17:39:23", "published_display": "30 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM:GYRE) added to Russell Small Cap Comp Value Benchmark", "summary": "Gyre Therapeutics, Inc. (NasdaqCM:GYRE) has been added to the Russell Small Cap Comp Value Benchmark. This inclusion follows several recent additions to various Russell indices, including the Russell 2000 Value, Russell 2000 Value-Defensive, Russell 2000 Growth-Defensive, Russell", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfd080f025", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:40:29", "published_display": "29 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value Benchmark", "summary": "Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 2000 Value Benchmark, according to a report published on June 29, 2026, by S&P Capital IQ. The biopharmaceutical company is focused on developing and commercializing therapies for liver fibrosis and other cond", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-2000-value-benchmark-ce7f5fdfd880f624", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:00:00", "published_display": "29 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm", "summary": "Kaskela Law LLC has initiated a shareholder investigation into Gyre Therapeutics, Inc. (NASDAQ: GYRE) to determine if the company's officers and directors violated securities laws or breached fiduciary duties. The firm encourages long-term Gyre shareholders to contact them to lea", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/gyre-therapeutics-gyre-kaskela-law-llc-announces-shareholder-inv-1183583", "source_name": "ACCESS Newswire", "published_at": "2026-06-29T06:00:00", "published_display": "29 Jun 2026 06:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Growth-Defensive Index", "summary": "Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 2000 Growth-Defensive Index. This inclusion comes alongside news of the company's F351 (hydronidone) drug for liver fibrosis advancing through regulatory processes in China, with an NMPA acceptance for a new d", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-2000-growth-defensive-index-ce7f5fdedb8af423", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T02:41:59", "published_display": "29 Jun 2026 02:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value-Defensive Index", "summary": "Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 2000 Value-Defensive Index. The biopharmaceutical company is focused on developing and commercializing F351 for MASH-associated fibrosis and expanding its pipeline in the PRC through Gyre Pharmaceuticals. Rece", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-2000-value-defensive-index-ce7f5fdedb8cff24", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T02:41:58", "published_display": "29 Jun 2026 02:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 3000E Value Benchmark", "summary": "Gyre Therapeutics, Inc. (NasdaqCM: GYRE) has been added to the Russell 3000E Value Benchmark. This inclusion follows several other recent additions to various Russell indices, including the Russell 2000 Value Benchmark, Russell 2000 Value-Defensive Index, and Russell 3000 Value B", "url": "https://www.marketscreener.com/news/gyre-therapeutics-inc-nasdaqcm-gyre-added-to-russell-3000e-value-benchmark-ce7f5fddd98bf422", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T01:08:55", "published_display": "29 Jun 2026 01:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Gyre Therapeutics, Inc. \u2013 NASDAQ:GYRE", "summary": "This page provides financial information for Gyre Therapeutics, Inc. (NASDAQ: GYRE), specifically its price to earnings forward. It is part of TradingView's market data offerings and includes various disclaimers regarding data sources.", "url": "https://www.tradingview.com/symbols/NASDAQ-GYRE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:45", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Gyre Therapeutics Inc \u2013 LS:A3EE5F", "summary": "This article provides financial data for Gyre Therapeutics Inc (LS:A3EE5F), specifically its forward price-to-earnings ratio. It is presented in a data-centric format from TradingView, offering an overview of the company's financial metrics. The content highlights the period, val", "url": "https://www.tradingview.com/symbols/LS-A3EE5F/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:38:51", "published_display": "26 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Gyre Therapeutics, Inc. \u2013 NASDAQ:GYRE", "summary": "This article focuses on the enterprise value to revenue forward metric for Gyre Therapeutics, Inc. (NASDAQ: GYRE). It indicates that the company's financial data is available for analysis on TradingView, which provides market, financial, and other relevant information for the pha", "url": "https://www.tradingview.com/symbols/NASDAQ-GYRE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:42", "published_display": "26 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Inc Actuals & Estimates (NASDAQ:GYRE)", "summary": "This article provides an overview of Gyre Therapeutics, Inc. (NASDAQ:GYRE) stock, including its current price, performance, analyst forecasts, and financial data. It covers historical price movements, volatility, market capitalization, and upcoming earnings reports, offering a co", "url": "https://www.tradingview.com/symbols/NASDAQ-GYRE/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T01:10:42", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) COO trades 11,000 shares, retains 700,000", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbzRmOWJZNGNvUDAxUUR6ZE5wNXQ1TVA3RVFybUx1TVc4Q0NFX3Fua3Jacy1YQXVYdm9ldUlHcUVLMmN5M182NXZCUU1MaDNoNElVZktpRFA3SW9tbllDNEhyS0Q3VXNWbm1SVXZyT281ZjYzZEF6WlZZMWUzby15NXkwdU9WN0dQeG00RVA4alNrcUhXekVELVdHS1BqNUtmUWJTQVAtQzhIWjdLVzgwNU1MNzAzZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Shareholders Approve Directors and Governance Measures", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQeTl1VVNZWUR0dEVObk1ieWJaZnY5cXFOektDb29ITVdsaWI5MFVjN2hUUUgwU0x4eXVPcjRkOVp1M3NqQlI4anRxeHhkajhlR1VXeDJyU2dSNXlZY0NaRVdKcjBHTWI3YWNnY3dRdWhsSklaREQwWHVmaGtkeFF0czFWcDdsTlI4X29KM3hReXEtUEhRUGpLcjR5a2JxSC0yUlhnQndYSV8xZEtWbFRua0V0UTJrbm92R1NpVHZhbnNpVm9oZVJKYkNlSEFSeDNqNGR1bEd2bnA3MThiX25XRks5YWR3c0QzTzROdnB3?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (NASDAQ: GYRE) investors back directors, pay and Series B conversion", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOdTJxeVNxN2kxUjNocGFWaVNRUXNLMzBFT2loeWxCYUJ0elhSQTRIbTViZExaQ2hSbm1xYmFxUUhJNTJGWExfTTZxQWJ0OFFmRXMzUmMzTTBpZm9zcHZLb2QxaVE4aVpkSlVSUV80N0tzU1Z3MU1WdzZ3VFdrZmZRajNnRTg2U0tBNUFKSktlSmhmdnBIRk5RQU5vbFFUY3FEMGphQ1hvZG1TbkhJd0RZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPdkFFRzV6Qjh6LUpsb3FfWm9hMEN2V1I1V2tLUUliUURleWhiTy1Eem5Kb0g2TWY4S3dwbWR4alpEZ25GN1g5czQ3cThyNnhST0hRRlJIUk1oMlVfbGxkX05IaC1ULXRpTi1JeWZ6WFB6U3UydTZ4LVpVM2xJN0ZSZWptaUpaVDRFdmtnODc5QUhYYWVtejhMZ2FVNzUzdXJLUWVDaTNLcFlQYy1ObUgxRHlWNXF2QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO of Gyre Therapeutics (NASDAQ: GYRE) receives 120,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxObkswNUtjS1FPbHJoMWpmcDluZURoaThtdkZTZWVtN3FmZVoyeWd2aERfQWZaM25lNlJfY1ZGMGx6UVU4Tk1jVnhJdDN3ZzQtQ3doTjdXNXgtRXgtUUZCODYwTXZLc3ZrQ1I5QU9mNlBockJEZFlKVEFCRTJRX2NkUmhFYkI5Tjc1b3I0dkd1dm0xTmF5Z2FIbE1oZVZSckN6VmVEcDdUQ0lQZlBPdU1BcldpS3BDdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug", "summary": "", "url": "https://finance.yahoo.com/news/gyre-therapeutics-says-china-regulator-215329042.html", "source_name": "MT Newswires", "published_at": "2026-05-12T21:53:29+00:00", "published_display": "12 May 2026 21:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment", "summary": "", "url": "https://finance.yahoo.com/news/gyre-therapeutics-announces-nmpa-acceptance-200500748.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gyre-therapeutics-reports-first-quarter-100000405.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T10:00:00+00:00", "published_display": "07 May 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOM2hGYk1kM3F2S0ZHMW01cGlyUDhlazZwZ2h6TlY2WHl4VmY5cTdaYzkzZW1WVEtVWFdYU0kwQnFpWHdLYUJyc2FuRm12WWtnRW40MWpRMHQ4aldpNzZ4QS0wTEJoSFpMMC0xVjJSTC14UHhXa0s2SVRQRFNxUkplYks2LXF3cEozNWZYZ3FJMlJPLWt1TGJtY0ltU0FUTjlOUkRHUVh3?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Completes $300 Million All-Stock Acquisition of Cullgen", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gyre-therapeutics-completes-300-million-144344832.html", "source_name": "MT Newswires", "published_at": "2026-05-04T14:43:44+00:00", "published_display": "04 May 2026 14:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gyre-therapeutics-completes-acquisition-cullgen-124700768.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T12:47:00+00:00", "published_display": "04 May 2026 12:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNdjVrMGMzeDhBckJDdkdXUm1RbVIxUDgtOGJPcUFGNkVEanFLNFdEeUw2aE9WM3YwTDBucWhPRldENTQ5Z2x3eXd3S3J1aVNxb3JYWkpVdWNKMmdNd0ZlSElONTZjYmd5ZjN6dEFLanM3Uk1uaFJBd3M4VHpKanVNU21JOEVVOU9xbEUxTA?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics Enters into Agreement to Acquire Cullgen", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxNWGxnNk9YdFZ1NU5MQTlBS1dGMW5fR0VWQW1vR3N2Y0pHajJWNkdCdHBIby1WVE5RSWdnRlFoTHlvbzFzVjZER1U2dEN5b0JOaUdjRk53bzRrX1I5QjZCSllhd0dCTmZEZVBZUmM2RE4yb2NFODlJbUdYNUl3dW5vSVpGNWwwSlpuMW5pZFp3Ty14TG5XTjBsN0trdFNKYkgzSjhXNTBKSG9vZUZUaVZmX2NjbUE5RmF4d1FETG55eHlTQzcxTEczbHFHNXl3ZEN0V2JkWlQwOFE2UlNZRl9uc0pNREU2LVgzY083cC1ZSmFuaFB3UzJMVXVZdjF0U0tnWVE2dlpQMHVzdGpVUXlPUHNsalduYVk3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNODNCTkJBNVEtWi1mQlN5ZmZFdHNmQVNBZ0VoNU0tY3dBQmtlNlFoOEFmR0J5b3ktb1pMdl80VEIwSlR6bVJETEpLQXV4UHJGM1ZuSG5yc2Jqcno1MUdPenBXa2dNdlJHZ0MxTTB6UnNlbkxidFNFbFA2cFVYYVA2R2lPRTJPUkNCMXFfRVVGb2JveTY0dmF0VDFURVA3S2RMNU41R2JzSUFtVUtDOU0xdWNHOUpOWFBPUmxaNU41cmlvUmp2OVVjUnhJcWFicGJqVEIzUDJ5d3dsWVZjRkoyUHoxckFTcmJyak1VcXctSEJFRU5ZcktzYlJR?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Gyre Therapeutics Stock Recover If Markets Fall?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQeHVfT3FPRzVLbm9rWktSSmJnaXJRdTdTX001bXdhWHhjbVlTenotRGtpQVh5NHZrS3lySUJBNkhTUmNOdXVKUkxVdU1iSVF5T2JBTHBEYU1Cd1dRdFpIT1V2TVE5akFrMVlGaDAwMkxOX0REVmVzRUVWWnNiVlJrSW9sbGgzMnJPVGpDSW9scGVUYUU4ZThaa2dvZ24tN2Q5eFVLcW1PQUlJZ2pHN1ZzWHFkOTQ3VlBOand2MEJXMA?oc=5", "source_name": "Trefis", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "272 Patients Enrolled \u2014 Gyre Therapeutics' Phase 3 Pirfenidone Trial Completes at 18 China Sites", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNakhKdmRnelI2aUZLWlhKR1Ruanp4cE1JaEJwYmtrZ1NCQ1d5VHJnS1lXbFpMVXJNZ2JUMkVGWTB2TnQ4WHhtX1pGeWdXQVFfM1I3X01MWDNSTXdyakJTQlkzaDdrRVRhOW5GRy1teXBnUWM2TDNBVDhtMm82TU9rdGNqU3hDbjNOb3JFVHdCZERwQnViQ1FlX1huVFE3ajk2UFJhVjh4MWtBTG1lSWRWOTh4aEhjUllOZXc?oc=5", "source_name": "Stock Titan", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gyre Therapeutics (GYRE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBtQjRvcXdKQjRleWlUckk4bEYyOWVGSTgwQnk2QWtQVzFjUmZrRjBmRWpIY1ZzVnkwWC1IcW9RYzhDaVVac2FCeHk5RmpvUG5FWmlJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:53:18+00:00", "published_display": "25 Apr 2025 00:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 53, "sentiment_summary": {"positive": 14, "negative": 6, "neutral": 33, "score": 55, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}], "positive_events": 14, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 6.05, "latest_week": "2026-07-17", "one_week_move": -7.2, "four_week_move": -3.2, "twelve_week_move": -18.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.241904, "market_dynamics_buy_signal": false, "relative_strength": -26.722599, "fair_value_gap": -43.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 53.8844, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.2% over one week, -3.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "Market source", "count": 8}, {"label": "TradingView", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "marketscreener.com", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 4}, {"label": "Regulatory and legal", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.2% over one week, -3.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Gyre Therapeutics Appoints Three New Members to its Board of Directors"}], "updated_at": "2026-07-18T11:15:47.034536+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}